5th European School of Pathology
The 5th European School of Pathology is going to take place in the Medical University of Varna, Bulgaria from 2nd to 4th May 2019, organized by the European Society of Pathology Bulgarian Pathology Association.
The 5th European School of Pathology is going to take place in the Medical University of Varna, Bulgaria from 2nd to 4th May 2019, organized by the European Society of Pathology Bulgarian Pathology Association.
For the 4th time Varna Medical University hosted the European School of Pathology. The course was attended by 56 participants from Portugal, Turkey, Russia, Macedonia, Croatia, Roumania and Bulgaria.
Welcome to the 30th European Congress of Pathology in Bilbao! From 8 to 12 September 2018 at the Euskalduna Conference Centre next to the river Nervión. The theme for the ECP 2018 is “Pathology: Path to Precision medicine”.
Latest medical research news. Researchers from Université Libre de Bruxelles discover that alkaloid found in Daffodils has anti-cancer properties. This alkaloid called haemanthamine works by triggering activation of anti-tumor surveillance pathway.
Fourth EScoP 2018 course is going to take place in Varna, Bulgaria between 17th – 19th May. The topic of the course is: “Update in Urinary System and Male Genital Tract Pathology” with top lecturers Maria R Raspollini, Maurizio Colecchia, Marina Scarpelli, Antonio Lopez Beltran and Rodolfo Montironi. The event will be held in Varna Medical University, which makes it possible for participants to follow a new online-based education in very interactive way.
Title: Advances in digestive neuroendocrine neoplasms course. EScoP 2017 is going to take place in Varna, Bulgaria on 29 and 30 September 2017.
Background: Autophagy is a catabolic process that has a vital role in cancer progression and treatment. Current chemotherapeutic agents, which target autophagy, result in growth inhibition in many cancer types. In this study, we examined the role of autophagy in breast cancer (BCa) patients as well as BCa cell lines. Methods: Tissue microarray was used to detect the expression of an autophagy marker, LC3B in BCa patients (normal/ hyperplasia ¼ 8; grade-I ¼ 15, grade-II ¼ 84, and grade-III ¼…
Positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between…
In the spectrum of breast cancers, categorization according to the four gene expression-based subtypes ‘Luminal A,’ ‘Luminal B,’ ‘HER2-enriched,’ and ‘Basal-like’ is the method of choice for prognostic and predictive value. As gene expression assays are not yet universally available, routine immunohistochemical stains act as surrogate markers for these subtypes. Thus, congruence of surrogate markers and gene expression tests is of utmost importance. In this study, 3 cohorts of primary breast cancer specimens (total n = 436) with up to…